Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
Interpace Biosciences reported a 34% increase in net revenue for 2020, totaling $32.4 million, driven by the pharma services sector. The fourth quarter saw a remarkable 129% revenue growth year-over-year, reaching $9.6 million. The company aims for a full-year revenue of $38 million to $40 million in 2021 and plans to achieve EBITDA breakeven by year-end. CEO Thomas Burnell highlighted significant savings and operational efficiency improvements, while CFO Tom Freeburg noted a positive impact from enhanced reimbursement rates and growing clinical services volume.
- 2020 net revenue increased 34% to $32.4 million.
- Fourth quarter revenue jumped 129% to $9.6 million.
- Full-year 2021 revenue guidance of $38 million to $40 million.
- On track to achieve EBITDA breakeven by end of 2021.
- Improved reimbursement rates for key services.
- Increased clinical services testing volume.
- Loss from continuing operations was approximately $(26.2) million in 2020.
- Adjusted EBITDA remained negative at $(15.4) million for 2020.
- Gross profit decreased slightly to 33% in 2020 from 34% in 2019.
- 2020 Full Year Net Revenue of
$32.4 Million Up34% vs Prior Year; Fourth Quarter Net Revenue of$9.6M Million Up129% vs Prior Year; - Provides Full Year 2021 Range of Revenues
- On Target to Achieve EBITDA Breakeven by 2021 Year End
PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.
“Fiscal 2020 was a challenging and transformational year for Interpace Biosciences. Since joining the company as President and CEO in December, we’ve made significant progress in our restructuring and reprioritization plan and are on target to realize our goal of achieving annualized savings of approximately
“As we progress forward in Fiscal 2021, we are realizing the positive impact of our recently improved reimbursement rates and seeing significant growth in our clinical services testing volume,” stated Tom Freeburg, CFO of Interpace. “We are providing full year revenue guidance in the range of
Full-Year 2020 Financial Performance as Compared to Full-Year 2019
- Net Revenue was
$32.4 million , an increase of34% versus the prior year which included pharma services net revenue starting in the third quarter of 2019. - Gross Profit was
33% and34% for full years 2020 and 2019, respectively. - Loss from Continuing Operations was approximately
$(26.2) million as compared to$(26.7) million for the prior year. - Adjusted EBITDA was
$(15.4) million as compared to$(16.6) million for the prior year.
Fourth Quarter 2020 Financial Performance as Compared to the Fourth Quarter of 2019
- Net Revenue was
$9.6 million , an increase of129% vs fourth quarter 2019. - Gross Profit was
32% for the fourth quarter 2020, vs -28% for the fourth quarter 2019. - Loss from Continuing Operations was
$(8.1) million vs$(10.6) million in the fourth quarter 2019. - Adjusted EBITDA was
$(4.1) million vs$(9.2) million in the fourth quarter 2019. - December 31, 2020 cash balance was
$2.8 million , net of restricted cash. March 15, 2021 cash balance was$3.4 million , net of restricted cash.
Recent Clinical and Reimbursement Highlights
We continue to generate and publish clinical evidence related to our key products, including ThyGeNEXT® and ThyraMIR® and PancraGEN® as well as our pipeline product, BarreGEN®.
Reimbursement expansion for our clinical services through 2020 is as follows:
- In December 2020, we executed an agreement with Regence Blue Cross Blue Shield of Washington State, Utah, Oregon, and Idaho.
- In December 2020, we executed an agreement with HealthNow New York, parent company of Blue Cross Blue Shield of Western New York, and Blue Cross Blue Shield of Northeastern New York.
- In December, 2020, we executed an agreement with Florida Blue/Blue Cross Blue Shield of Florida, which was effective January 1, 2021.
- In December 2020, Medicare increased reimbursement for our ThyGeNEXT® test from
$600 t o$2,900. We began realizing reimbursement at this higher rate starting in January 2021.
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has five commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, a “molecular only” version of PancraGEN® that provides physicians a snapshot of a limited number of factors; ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX® that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a clinical evaluation program (CEP) whereby we gather information from physicians using BarreGEN® to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.
Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, while also improving patient care.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements including, but not limited to, the adverse impact of the COVID-19 pandemic on the Company’s operations and revenues, the substantial doubt about the Company’s ability to continue as a going concern, the possibility that the Company’s estimates of future revenue may prove to be materially inaccurate, the Company’s history of operating losses, the Company’s ability to adequately finance its business, the Company’s ability to repay its
Contacts:
Investor Relations
Edison Group
Joseph Green/ Megan Paul
(646) 653-7030/7034
jgreen@edisongroup.com/mpaul@edisongroup.com
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)
| Three Months Ended | Years Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue, net | $ | 9,646 | $ | 4,214 | $ | 32,398 | $ | 24,220 | ||||||||
| Cost of revenue | 6,517 | 5,399 | 21,673 | 15,888 | ||||||||||||
| Gross Profit | 3,129 | (1,185 | ) | 10,725 | 8,332 | |||||||||||
| Sales and marketing | 2,478 | 2,990 | 9,254 | 11,116 | ||||||||||||
| Research and development | 673 | 778 | 2,795 | 2,810 | ||||||||||||
| General and administrative | 7,288 | 4,748 | 20,770 | 14,363 | ||||||||||||
| Acquisition related expense | - | - | - | 2,534 | ||||||||||||
| Acquisition amortization expense | 1,115 | 1,115 | 4,461 | 3,989 | ||||||||||||
| Change in fair value of contingent consideration | (489 | ) | (44 | ) | (489 | ) | (44 | ) | ||||||||
| Total operating expenses | 11,065 | 9,587 | 36,791 | 34,768 | ||||||||||||
| Operating loss | (7,936 | ) | (10,772 | ) | (26,066 | ) | (26,436 | ) | ||||||||
| Interest accretion expense | (135 | ) | (109 | ) | (549 | ) | (440 | ) | ||||||||
| Other (expense) income, net | (6 | ) | 209 | 467 | 196 | |||||||||||
| Loss from continuing operations before tax | (8,077 | ) | (10,672 | ) | (26,148 | ) | (26,680 | ) | ||||||||
| Provision for income taxes | 10 | (47 | ) | 53 | (28 | ) | ||||||||||
| Loss from continuing operations | (8,087 | ) | (10,625 | ) | (26,201 | ) | (26,652 | ) | ||||||||
| Loss from discontinued operations, net of tax | (56 | ) | (38 | ) | (250 | ) | (88 | ) | ||||||||
| Net loss | (8,143 | ) | (10,663 | ) | (26,451 | ) | (26,740 | ) | ||||||||
| Less adjustment for preferred stock deemed dividend | - | - | (3,033 | ) | - | |||||||||||
| Less dividends on preferred stock | - | (354 | ) | - | (429 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (8,143 | ) | $ | (11,017 | ) | $ | (29,484 | ) | $ | (27,169 | ) | ||||
| Basic and diluted loss per share of common stock: | ||||||||||||||||
| From continuing operations | $ | (2.00 | ) | $ | (2.86 | ) | $ | (7.26 | ) | $ | (7.23 | ) | ||||
| From discontinued operations | (0.01 | ) | (0.01 | ) | (0.06 | ) | (0.02 | ) | ||||||||
| Net loss per basic share of common stock | $ | (2.01 | ) | $ | (2.87 | ) | $ | (7.32 | ) | $ | (7.25 | ) | ||||
| Weighted average number of common shares and | ||||||||||||||||
| common share equivalents outstanding: | ||||||||||||||||
| Basic | 4,043 | 3,834 | 4,029 | 3,746 | ||||||||||||
| Diluted | 4,043 | 3,834 | 4,029 | 3,746 | ||||||||||||
Selected Balance Sheet Data
($ in thousands)
| December 31, | December 31, | |||||||
| 2020 | 2019 | |||||||
| Cash and cash equivalents | $ | 2,772 | $ | 2,321 | ||||
| Total current assets | 14,122 | 16,510 | ||||||
| Total current liabilities | 18,233 | 17,292 | ||||||
| Total assets | 45,681 | 51,540 | ||||||
| Total liabilities | 28,228 | 29,847 | ||||||
| Total stockholders’ deficit | (29,083 | ) | (4,479 | ) | ||||
Selected Cash Flow Data
($ in thousands)
| For the Years Ended | ||||||||
| December 31, | ||||||||
| 2020 | 2019 | |||||||
| Net loss | $ | (26,451 | ) | $ | (26,740 | ) | ||
| Net cash used in operating activities | $ | (14,579 | ) | $ | (18,957 | ) | ||
| Net cash used in investing activities | (1,575 | ) | (13,947 | ) | ||||
| Net cash provided by financing activities | 16,605 | 29,157 | ||||||
| Change in cash and cash equivalents | 451 | (3,747 | ) | |||||
| Cash and equivalents, Beginning | 2,321 | 6,068 | ||||||
| Cash and equivalents, Ending | $ | 2,772 | $ | 2,321 | ||||
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.
In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, acquisition related expenses, transition expenses, non-cash stock based compensation and ESPP plans, interest and taxes, and other non-cash expenses including asset impairment costs, bad debt expense, receipt of stimulus grants, loss on extinguishment of debt, goodwill impairment and change in fair value of contingent consideration, and warrant liability. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| Quarters Ended | Years Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Loss from continuing operations (GAAP Basis) | $ | (8,087 | ) | $ | (10,625 | ) | $ | (26,201 | ) | $ | (26,652 | ) | ||||
| Bad debt expense | 335 | - | 585 | 499 | ||||||||||||
| Acquisition related expense | - | - | - | 2,534 | ||||||||||||
| Receipt of HHS stimulus grant | - | - | (650 | ) | - | |||||||||||
| Transition expenses | 1,780 | - | 2,578 | 836 | ||||||||||||
| Legal and professional services | - | - | 495 | - | ||||||||||||
| Depreciation and amortization | 1,399 | 1,360 | 5,501 | 4,524 | ||||||||||||
| Stock-based compensation | 861 | 289 | 2,242 | 1,535 | ||||||||||||
| Taxes | 10 | (47 | ) | 53 | (28 | ) | ||||||||||
| Interest accretion expense | 135 | 109 | 549 | 440 | ||||||||||||
| Mark to market on warrant liability | 1 | (244 | ) | (61 | ) | (279 | ) | |||||||||
| Change in fair value of contingent consideration | (489 | ) | (44 | ) | (489 | ) | (44 | ) | ||||||||
| Adjusted EBITDA | $ | (4,055 | ) | $ | (9,202 | ) | $ | (15,398 | ) | $ | (16,635 | ) | ||||
FAQ
What were Interpace Biosciences' revenue figures for 2020?
How did Interpace's fourth quarter revenue compare to last year?
What is Interpace's revenue guidance for 2021?
Is Interpace Biosciences on track for EBITDA breakeven in 2021?
What were the significant changes in reimbursement rates for Interpace's tests?
